Literature DB >> 30340093

Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients.

Ning Tang1, Xiong Wang1, Dengju Li2, Ziyong Sun3.   

Abstract

BACKGROUND: The recently published PLASMIC score was shown to be an excellent diagnostic model to identify patients with severe ADAMTS-13 deficiency. However, it is unclear if this score is suitable for Chinese patients with suspected thrombotic thrombocytopenic purpura (TTP).
METHODS: We retrospectively studied a Chinese cohort of 134 consecutively hospitalized patients with thrombotic microangiopathy, ADAMTS-13 test results, and clinical information between January 2015 and June 2018, the PLASMIC score's distinguishing ability in this cohort was evaluated. We also combined the lactate dehydrogenase (LDH)-to-aspartate aminotransferase (AST) ratio with the PLASMIC score to determine its predictive value for TTP in pregnancy.
RESULTS: In this Chinese cohort, 39 patients were diagnosed with TTP using ADAMTS13 testing. When stratified at high (score, 6-7) vs. low-intermediate (score, 0-5) risk, the PLASMIC test predicted TTP with a positive predictive value of 51%, negative predictive value of 92%, sensitivity of 85%, and specificity of 58%. In pregnant patients, a combination of the PLASMIC score of 6-7 and LDH-to-AST ratio of ≥5.5 showed a higher positive predictive value for TTP compared with the PLASMIC score alone (71% vs. 35%, P < 0.001). Removing the component MCV < 90 fL from the PLASMIC score did not reduce its distinguishing power, as measured using the C statistic (0.837, 95%CI 0.767-0.907 vs. 0.797, 95%CI 0.718-0.877; P = 0.771).
CONCLUSIONS: Combination with a higher LDH-to-AST ratio improves the positive predictive value of the PLASMIC score in pregnant patients. A simpler score without MCV < 90 fL can be used to identify TTP in Chinese patients.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADAMTS 13 protein; Thrombotic thrombocytopenic purpura; Validation studies

Mesh:

Substances:

Year:  2018        PMID: 30340093     DOI: 10.1016/j.thromres.2018.10.010

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  6 in total

1.  Comparison of Clinical Scoring Systems in the Management of Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia

Authors:  Mehmet Baysal; Elif Ümit; Hakkı Onur Kırkızlar; Ahmet Muzaffer Demir
Journal:  Turk J Haematol       Date:  2020-11-09       Impact factor: 1.831

2.  Pregnancy-associated thrombotic thrombocytopenic purpura complicated by Sjögren's syndrome and non-neutralising antibodies to ADAMTS13: a case report.

Authors:  Lu Zhou; Yu Zhu; Miao Jiang; Min Su; Hong Liu; Jian Su; Xiaofan Liu; Yizhi Jiang; Hui Mu; Jie Yin; Li Yang; Haiyan Liu; Weidong Pan
Journal:  BMC Pregnancy Childbirth       Date:  2021-12-03       Impact factor: 3.007

3.  Thrombotic thrombocytopenic purpura complicated with acute aortic dissection: A case report.

Authors:  Mei-Juan Huang; Jin-Niu Deng; Li-Li Gao; Jian-Feng Zhou
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

4.  Proteinuria Increases the PLASMIC and French Scores Performance to Predict Thrombotic Thrombocytopenic Purpura in Patients With Thrombotic Microangiopathy Syndrome.

Authors:  Nicolas Fage; Corentin Orvain; Nicolas Henry; Chloé Mellaza; François Beloncle; Marie Tuffigo; Franck Geneviève; Paul Coppo; Jean François Augusto; Benoit Brilland
Journal:  Kidney Int Rep       Date:  2021-11-16

5.  Thrombotic Thrombocytopenic Purpura Triggered by Acute Myeloid Leukemia: A Case Report.

Authors:  Ijele Adimora; Cristhiam M Rojas Hernandez
Journal:  Am J Case Rep       Date:  2022-08-30

6.  Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals.

Authors:  Angela Liu; Noor Dhaliwal; Harshvardhan Upreti; Jamil Kasmani; Kathryn Dane; Alison Moliterno; Evan Braunstein; Robert Brodsky; Shruti Chaturvedi
Journal:  Transfusion       Date:  2020-11-12       Impact factor: 3.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.